About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Docs on Twitter


Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« AstraZeneca Spins Off New Biotech Company | Main | Judge Michel Doesn't Think Much of Senate Bill S. 1145, Either »

February 20, 2008

Pfizer to Acquire Encysive Pharmaceuticals

    By Jason Derry --

Pfizer Pfizer Inc. has announced that it has an agreement in place to acquire Encysive Pharmaceuticals Inc. for about $195 million.  Encysive is a biotechnology company that has a product currently marketed in the European Union, and several other foreign markets, for treating pulmonary arterial hypertension.  The product, THELIN (sitaxsentan sodium), is an endothelin A receptor antagonist.  THELIN has been approved in Australia and Canada, but is still awaiting approval in the U.S.  Pfizer has indicated that it will conduct the necessary Phase III trial to move the Encysive_pharmaceuticals drug toward approval.  Encysive has several other drug candidates in its pipeline in various clinical stages of development.  Pfizer has indicated that Encysive will eventually be merged with a Pfizer subsidiary.

For additional information, please see:

• Reuters report

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 10:32 PM in Biotech/Pharma Business, Licensing |

Comments

The comments to this entry are closed.

March 2023

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...